Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Cervarix in Women Aged 15-55 Years
NCT00196937Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2004
- Primary completion
- Dec 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, open-label trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection (3 arms), sponsored by GSK. Primary endpoints: Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies at Month 7 and Anti-HPV-16/18 Antibody Titers Assessed by ELISA at Month 48. Started Oct 2004; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00196937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00196937.